The deal includes the supply of high multiplex real-time PCR reagents for the Hologic Panther Fusion system that is presently in development.
Seegene will develop and produce multiplex assays by using DPO, TOCE, and MuDT technologies for Hologic's next generation molecular diagnostics system.
Panther system is a fully automated sample-to-answer instrument, which enables to avoid batch processing and automates all aspects of nucleic acid testing on a single and integrated platform.
MuDT technology is said to offer perfection of qPCR technology by simultaneously identifying and quantifying multiple targets in a single fluorescence channel.
Financial terms of the deal have not been disclosed.
Hologic diagnostic president Tom West said: “Seegene's multiplex reagents will enable simultaneous detection and quantification of various target genes, further broadening the menu of Hologic's Panther Fusion system and strengthening its leadership position in the molecular diagnostic market."
Seegene founder and CEO Dr Jong – Yoon Chun said: Our agreement with Hologic represents another meaningful milestone to Seegene's global expansion initiatives in the molecular diagnostics market.
“We expect to accelerate technological standardization in the MDx market by building up capabilities of assay development applying on various platforms."
Hologic is engaged in the development and manufacturing of diagnostic products, medical imaging systems and surgical products.
Seegene is involved in the development of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx).
Image: Seegene and Hologic to develop high multiplex molecular diagnostic assays. Photo: courtesy of Suwit Ritjaroon/ FreeDigitalPhotos.net.
